Development of Reduced Vancomycin Susceptibility in Methicillin‐SusceptibleStaphylococcus aureus | Zendy

Satish K. Pillai | Zendy; Christine Wennersten | Zendy; Lata Venkataraman | Zendy; George M. Eliopoulos | Zendy; Robert C. Moellering | Zendy; Adolf W. Karchmer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of Reduced Vancomycin Susceptibility in Methicillin‐SusceptibleStaphylococcus aureus

Author(s) -

Satish K. Pillai,

Christine Wennersten,

Lata Venkataraman,

George M. Eliopoulos,

Robert C. Moellering,

Adolf W. Karchmer

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/605636

Subject(s) - vancomycin , daptomycin , staphylococcus aureus , microbiology and biotechnology , antibiotics , medicine , autolysis (biology) , methicillin resistant staphylococcus aureus , minimum inhibitory concentration , staphylococcal infections , biology , bacteria , biochemistry , genetics , enzyme

Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains. We report the development of reduced vancomycin susceptibility in a series of clonally related, methicillin-susceptible S. aureus (MSSA) clinical isolates. This isogenic series permitted us to determine whether the evolution of reduced vancomycin susceptibility in MSSA is similar to that seen in MRSA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research